Mylan Misconduct Fine In Actos Suit Could Alter Future Generic Challenges
Executive Summary
Generic drug manufacturers may be more cautious in challenging the validity of a brand name company's patent after an appeals court affirmed that Takeda was entitled to $16.8 million in attorneys fees in litigation over its diabetes drug Actos
You may also be interested in...
180-Day Exclusivity Decision On Acarbose Illustrates Importance Of ANDA Quality
FDA's decision to deny Cobalt 180-day exclusivity for its ANDA of acarbose (Bayer's diabetes treatment Precose) illustrates the importance for generic firms of submitting high-quality applications
Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops
In deciding for Takeda, judge says Mylan and Alphapharm also disregarded court orders and used faulty witnesses during their patent challenges.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.